Chevy Chase Trust Holdings LLC Has $10.30 Million Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Chevy Chase Trust Holdings LLC decreased its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 2.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,600 shares of the medical research company’s stock after selling 1,408 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.06% of Laboratory Co. of America worth $10,298,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Pathway Financial Advisers LLC acquired a new position in shares of Laboratory Co. of America in the 1st quarter valued at about $30,000. McClarren Financial Advisors Inc. increased its stake in Laboratory Co. of America by 313.2% in the 1st quarter. McClarren Financial Advisors Inc. now owns 219 shares of the medical research company’s stock valued at $48,000 after buying an additional 166 shares during the period. Quent Capital LLC lifted its position in Laboratory Co. of America by 88.4% in the 2nd quarter. Quent Capital LLC now owns 260 shares of the medical research company’s stock worth $53,000 after buying an additional 122 shares in the last quarter. Concord Wealth Partners boosted its stake in shares of Laboratory Co. of America by 50.3% during the 1st quarter. Concord Wealth Partners now owns 275 shares of the medical research company’s stock valued at $60,000 after buying an additional 92 shares during the period. Finally, Disciplined Equity Management Inc. purchased a new position in shares of Laboratory Co. of America during the 4th quarter valued at $68,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Laboratory Co. of America

In other news, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $227.05, for a total transaction of $454,100.00. Following the sale, the executive vice president now owns 3,670 shares of the company’s stock, valued at approximately $833,273.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Kerrii B. Anderson sold 586 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $225.00, for a total value of $131,850.00. Following the sale, the director now owns 14,722 shares of the company’s stock, valued at $3,312,450. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $227.05, for a total transaction of $454,100.00. Following the transaction, the executive vice president now owns 3,670 shares of the company’s stock, valued at approximately $833,273.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,679 shares of company stock worth $6,716,306. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Performance

Shares of Laboratory Co. of America stock traded up $3.21 during trading on Wednesday, reaching $228.89. The company’s stock had a trading volume of 132,730 shares, compared to its average volume of 708,492. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $238.46. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. The firm has a market cap of $19.30 billion, a price-to-earnings ratio of 45.67, a price-to-earnings-growth ratio of 1.76 and a beta of 1.05. The business’s fifty day moving average price is $212.10 and its 200-day moving average price is $210.34.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.94 EPS for the quarter, topping the consensus estimate of $3.78 by $0.16. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.19 billion. During the same period in the previous year, the business posted $3.42 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities research analysts predict that Laboratory Co. of America Holdings will post 14.84 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Thursday, August 29th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Thursday, August 29th. Laboratory Co. of America’s dividend payout ratio is currently 57.95%.

Analyst Upgrades and Downgrades

LH has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. UBS Group boosted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Barclays raised their price objective on shares of Laboratory Co. of America from $213.00 to $249.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. StockNews.com raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Bank of America raised their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a report on Monday, August 5th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $247.42.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).